Machine learning approaches for the identification of real-world predictors of mepolizumab response
BACKGROUND: Mepolizumab improves control and reduces clinically significant exacerbations in severe asthma patients. Further research is needed to understand factors influencing patient response. OBJECTIVE: Identify predictors of response to mepolizumab using machine learning techniques. METHODS: Thirty clinically relevant features from the REALITI-A dataset were analyzed. Response to mepolizumab was defined as change in clinically significant exacerbations at Year 1 post-exposure, being free from clinically significant exacerbations at Year 1, and being free from clinically significant exacerbations at both Year 1 and Year 2 post-exposure for primary, secondary, and exploratory analyses, respectively. Linear/logistic regression, random forest, and XGBoost models were tested. The best-performing model based on R2 or classification accuracy was used for feature selection. A SHapley Additive exPlanations post-hoc analysis was conducted. RESULTS: The primary and secondary analyses included 685 patients; the exploratory analysis included 529 patients. Using XGBoost for the primary analysis, higher pre-exposure clinically significant exacerbations rate, lower body mass index, total immunoglobulin E, lower baseline activity impairment, and lower baseline Asthma Control Questionnaire-5 score were top predictors. For the secondary analysis, the random forest model identified lower pre-exposure clinically significant exacerbations rate, residency outside the United Kingdom, and lower baseline Asthma Control Questionnaire-5 score, body mass index, and baseline activity impairment as top predictors. For the exploratory analysis, XGBoost identified residency outside the United Kingdom, and lower pre-exposure clinically significant exacerbations rate, baseline Asthma Control Questionnaire-5 score, eosinophil levels, and body mass index as top predictors. CONCLUSION: Machine learning models identified key predictors of response to mepolizumab, which could guide clinical decision-making and improve patient outcomes in severe asthma patients.
Authors
- Lingjiao Zhang (ORCID: https://orcid.org/0000-0003-0700-4584)
- Rafael Alfonso‐Cristancho (ORCID: https://orcid.org/0000-0002-7060-5131)
- Koyo Usuba (ORCID: https://orcid.org/0000-0002-8850-2341)
- Natalie Nightingale (ORCID: https://orcid.org/0000-0001-9988-216X)
- Xinyang Liu (ORCID: https://orcid.org/0000-0002-5827-7729)
- Tim Tian Yu Han
- Ali Tehrani
- Peter Howarth
Institutions
- GlaxoSmithKline (United Kingdom) (GB)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1371/journal.pone.0362402
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00